CD44 and allergic disease: Our findings therefore provide a novel insight into the role of hypoxia in programming DCs primed Th2 responses via a KIF2A/MT1-MMP/CD44 pathway and implicate that hypoxia might be a promising therapeutic approach in allergic diseases.